Alcon AG vs Twist Bioscience Corp — how do they compare? Alcon AG trades at $72.48 (market cap $36.44B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Alcon AG is far larger — about 4.7× Twist Bioscience Corp's market cap, and Alcon AG pays a 0.48% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| ALC | TWST | |
|---|---|---|
Market Cap | $36.44B | $7.72B |
Sector | Health | Health |
52-Week High | $90.12 | $124.88 |
52-Week Low | $62.02 | $24.16 |
Enterprise Value | $40.28B | $7.65B |
Dividend Yield | 0.48% | — |
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →